ABSTRACT
INTRODUCTION
The prescription of antiulcer medications and their costs both in the in-hospital and outpatient environment have increased during recent years. In England, the costs for antiulcer medications reached € 100,000,000 in 2006, with omeprazole as the most sold prescription. In the United States, esomeprazole sales alone surpassed € 4.5 billion in 2009, whereas the whole pharmacologic group constituted by the proton pump inhibitors was the third most sold group in the country (1) (2) (3) .
In the inpatient environment, antiulcer medications use has been justified for stress ulcer prophylaxis and treatment, but few of the patients truly require the prescription (4) (5) (6) . Additionally, they have been used for different indications from those recommended, as polymedication, with the exception of gastrolesive drugs, which present clearer indications for their prescription, including criteria such as age and risk factors for upper gastrointestinal hemorrhage, and are not simply used as mucosa protectors (5) (6) (7) .
Furthermore, the increased risk of adverse reactions in patients with multiple medications must be considered when they also start receiving antiulcer medication; indeed PPI have been associated with atrophic gastritis, interstitial nephritis, osteoporosis, gynecomastia, arrhythmias, and pneumonia, among others, and H2 antagonists (AntiH2) have been associated with diarrhea, dizziness, headache, acid hyper secretion rebound effect, and arrhythmias, as well as hematologic and hepatic alterations. These drugs may also mask certain illnesses, and multiple studies in different countries all around the world have shown excess costs incurred by health systems as a consequence of inadequate use of antiulcer medications that it has reported up to 80 % of the cases (4, (11) (12) (13) (14) (15) .
There have been no studies published in Colombia about the prescription and indication of antiulcer medications in the inpatient environment, and on the continent these kinds of studies are few in number. So it was decided to determine and evaluate the patterns of prescriptionindication of these medications in a tertiary level hospital in a Colombian city and make an economic analysis of the excess cost that their unjustified use generates, in order to create educational measures for their management in patients and healthcare givers.
pATIeNTS AND MeTHODS
A cross-sectional study of prescription indication in patients hospitalized in the Hospital Universitario San Jorge (HUSJ), in Pereira, to whom at least one antiulcer medication was prescribed between July 1 st and 31 st , 2012. The selected month was chosen randomly, avoiding January and December because those months show atypical behavior in the number of hospitalizations; the information was collected from the whole population, older than 18 years old, of any gender, who received attention in the services of urgent care, observation, internal medicine, surgery, the intermediate care unit, intensive care unit, gynecology and obstetrics. The dispensation of the drugs was reported by the pharmacy of the hospital and the clinical records of the patients, with prior authorization by the hospital, were reviewed. A database of drug formulation was validated and reviewed by the authors to minimize, selection and information bias.
The main variables were the determination of adequate or inadequate first antiulcer treatment prescribed at the time of hospitalization and the same determination during the course of hospitalization. Switches or additions of antiulcer drugs in the same patient (route of administration or an additional antiulcer medication) were considered, and each was analyzed as a new antiulcer therapy.
Inappropriate prescription of antiulcer therapy was defined as outlined in Clinical Practice Guidelines for the use of PPI from the Zaragoza I workgroup and Clinical Practice Guidelines from the Australian Government Health Department (16, 17) . Their use in non-ulcer dyspepsia, peptic disease, gastroesophageal reflux disease, Helicobacter pylori eradication, Zollinger-Ellison Syndrome, Barrett's esophagus, histological diagnostic of gastritis, and when the patient use a gastrolesive drugs, were considered adequate indications for antiulcer medication therapy. Indication of stress ulcer prophylaxis according to the criteria of the American College of Gastroenterology (18) was added to the accepted indications. Other indications with weak evidence for use, such as esophageal varices, upper gastrointestinal endoscopy with biopsy, personal history of gastritis without diagnostic confirmation and anemia without determining etiology were also accepted (16, 17) .
The study included socio-demographic variables (age, gender, affiliation with the Health System, city of provenance, origin of remission); clinical variables (main diagnosis, secondary diagnoses, length of hospital stay, confirmatory analytical test for peptic ulcer, upper gastrointestinal bleeding and acid-peptic disease) (16) (17) (18) ; and pharmacological variables (prescribed antiulcer medications, route of administration, duration, dosage, other medications, hospital service where antiulcer therapy started, higher complexity hospitalization service reached like critic care unit) including polypharmacy -minor (2 or 3 concomitant drugs), moderate (4-5) and major (≥ 6) (5).
For the economic analysis the defined daily dose per bed-day (DHD) was calculated, the reference price of each drug was taken and the cost per 100 bed-days was obtained. The average number of days that each patient received antiulcer medications and the costs of each drug were determined (market reference rate: € 1 per COP$ 2259.3 -July 2012).
The study was approved by the Bioethics Committee of the Universidad Tecnológica de Pereira in the category of "research without risk," according to Resolution 8430/93 of Colombia's Ministry of Health and the principles of the Declaration of Helsinki.
Data analysis was done using the statistical package SPSS-21.0 (IBM, USA) for Windows. Student's t test or ANOVA were used for comparisons of quantitative variables and c 2 for categorical variables. Bivariate analyses were conducted to establish statistical associations and logistic regression models were applied using inadequate antiulcer indication at admission and during hospitalization as dependent variables, and those that were significant in the bivariate analysis as independent variables. Statistical significance was predetermined to be p < 0.05.
ReSULTS
Of 853 inpatients 75 were discarded for having incomplete information, so the analysis was performed with 778 patients. The socio-demographic and clinical characteristics of hospitalization of these patients can be seen in table I. There was a predominance of males, with an average hospital stay of 12.0 ± 15.7 days (range 1-200 days). 
First antiulcer treatment
The most widely used antiulcer medication at the beginning of hospitalization was ranitidine in 438 patients (56.3 %) followed by omeprazole in 332 cases (42.7 %) and sucralfate in only 8 users (1.0 %). No justification for the prescription of antiulcer treatments in 377 patients (48.5 %) was found. The mean duration of the prescription was 8.7 ± 12.3 days (range: 0-131 days). Of these, 36.1 % of patients (n = 281) received the antiulcer medication for more than ten days. Oral was the most frequent route of administration (n = 395, 50.8 %).
The first antiulcer therapy was prescribed concomitantly with anticoagulants in 399 patients (51.3 %), with antihypertensives in 397 cases (51.0 %), and analgesics/ antipyretics in 391 (50.2 %), among other drugs. It was found that 42 patients (5.4 %) concomitantly received another antiulcer medication. The frequency of use of antiulcer medications in patients with major polypharmacy was 419 cases (53.9 %), followed by patients with minor polypharmacy in 202 cases (26.0 %) and moderate in 157 (20.2 %) patients.
Indication-prescription of treatments with antiulcer medications
There were 554 patients (71.2 %) who received only a single antiulcer therapy, but 224 (28.8 % of cases) were given a new therapy with antiulcer medications at a different time in their hospitalization, 136 corresponding to omeprazole (60.7 % of the patients), 73 to ranitidine (32.5 %) and 15 to sucralfate (6.7 %). Additionally, there were 74 patients (9.5 % of total cases) whose antiulcer treatment was modified yet again during hospitalization, another 11 patients (1.4 % of all cases) with a third modification, and finally 2 patients (0.2 %) who either received 5 distinct antiulcer medications or with different routes of administration during hospitalization.
It was found that in 352 patients (45.2 % of cases), the antiulcer medication was accompanied by the use of NSAIDs or anticoagulants with or without risk factors or in combination with other gastrolesive drugs. Furthermore, 248 patients (31.9 %) were receiving anti-platelet agents. The antiulcer treatments were prescribed concomitantly with anticoagulants in 553 patients (71.0 %), with antihypertensive drugs in 547 cases (70.3 %), with analgesic-antipyretics in 498 (64.0 %) and with opioids in 350 (45.0 %), among others. Table II shows the indications for which antiulcer treatment was initiated in patients.
Upon a search of all antiulcer medications during the course of hospitalization, the most prescribed was found to be ranitidine in 524 patients (67.3 % of cases), followed by omeprazole in 491 patients (63.1 %) and sucralfate in 39 patients (5.0 %). It was determined that 336 (43.2 %) of patients didn´t have an appropriate indication during hospitalization. In addition, 95 patients (12.2 %) received more than one antiulcer medication simultaneously.
Multivariate analysis

First antiulcer treatment
In a multivariate analysis of the misuse of initial antiulcer medications and the variables associated with statistically significant differences in the bivariate analysis, it was determined that giving the antiulcer medication concomitantly with an analgesic-antipyretic, other antibiotics different from beta-lactam, macrolides and tetracyclines, with antiemetics, or if the patient had minor polypharmacy, were all associated with a risk for improper prescription of antiulcer treatment. It was found that a diagnosis of pneumonia, sepsis, intravenous administration, antiplatelet agents, vasopressors and anticoagulants were all associated as protective factors for inappropriate prescription of antiulcer treatment (Table III) .
Antiulcer treatment throughout hospitalization
A multivariate analysis between the inappropriate use of antiulcer medication during the course of hospitalization and the statistically significant variables in the bivariate analysis showed that concomitant administration of an analgesic was associated with an inappropriate prescription ( Table IV) . The intravenous route of administration, the use of anti-platelet or anticoagulant agents, or having a diagnosis of heart failure were associated as protective factors for inappropriate prescription of antiulcer medications.
economic analysis
Oral omeprazole in 20 mg capsules was used at the rate of 11.0 DHD and the 40 mg injectable solution at 70 DHD, while 150 mg ranitidine tablets were used at 65.5 DHD and the injectable solution at 8.3 DHD.
The monthly cost for antiulcer treatments not indicated for all patients was € 3,335.6. The annual estimated cost for the improper prescription of antiulcer medications was € 16,770.0 DHD per 100 beds per day. Table V shows the economic analysis for each group of antiulcer medications according to their prescribed units, DHD and reference cost for each, as well as costs for oral and intravenous presentations.
DISCUSSION
There was an inappropriate prescription in 48.5 % of patients for the first antiulcer medication prescribed and in 43.2 % of patients at the prescription throughout their entire hospitalization, accounting for an estimated unjustified annual cost of € 16,770 per 100 beds per day, establishing an association of risk with different variables for that inappropriate prescribing.
A significant unjustified use of antiulcer medications has been found, and variables and additional associated costs identified (19) . Nardino et al. and various studies in countries like Saudi Arabia, the United States of America and Europe showed inadequate indications for antiulcer medications (PPI's and antiH2) that ranged between 40.0 % and 73.0 %, with variations in the health centers' care level and the populations studied. Other studies analyzed cases of stress ulcer prophylaxis, which showed 22.0 % to 33.8 % of prescriptions were inappropriate (20) (21) (22) (23) (24) (25) (26) , or the unjustified formulation of antiulcer medication at the time of hospital discharge ranging from 24.0 % to 69.0 % (27,28), this being a new point of interest for future research. All these data on prescriptions are higher than those found in our population. Although most of these studies are old and based on evidence available at the time, the new scientific information on recommended use of antiulcer medications is one strength of this research regarding previous ones (20) (21) (22) (23) (24) (25) (26) (27) (28) .
Additionally, indicators show there is a difficulty in retiring antiulcer prescriptions once initiated (29, 30) . In the United Kingdom, 51.0 % of initial in-hospital prescriptions didn't have an adequate indication (30, 31) , a similar percentage to the one found in our work (48.5 %); it was found that 5.3 % of patients who initially received an unjustified antiulcer drug prescription subsequently had an indication during their hospitalization, while the remaining 43.2 % still had no indication for their use.
The most prescribed drug was ranitidine, a finding that does not align with what can be found in the literature, where PPI's are on top (24, 25, 32, 33) . Nonetheless, we must mention that both oral and intravenous omeprazole were the antiulcer drugs with the highest accumulated cost in our study. It is also important to highlight the economic difference between oral and parenteral presentations, this difference representing an important point for intervention and one about which no literature can actually be found.
Guide implementation (such as the ones used in this work) has been shown to decrease drug prescriptions, inappropriate use and associated costs (34) . A study in the USA estimated annual savings of up to US$ 102,895 on patient care and US$ 11,333 on drug costs when stress-ulcer prophylaxis guides were use in an Intensive Care Unit (35) , whilst a similar study in Canada demonstrated that daily drug costs were reduced from C$ 2.50/day to C$ 1.30/day by using these protocols (36) . A study carried out by our research group showed that US$ 2,202,590 are wasted on unjustified PPI prescriptions in ambulatory care populations. These indicators allow comparisons among populations and hospitals, but are not described in the majority of studies (3).
Nardino et al. showed that university hospitals made more adequate antiulcer drug prescriptions, similar to the one in this study, when compared to other types of institution (20) . We must mention that we included multiple diagnoses, procedures and treatments as an indication for antiulcer use; this might also have contributed to a reduced inappropriate use of antiulcer drugs in comparison to other studies (20) (21) (22) (23) (24) (25) (26) (27) (28) .
Among this work's limitations it must be considered that this study does not allow analysis of the reasons for which health care professionals prescribed antiulcer drugs unless they made it obvious on the Medical History, so it cannot be assumed that the physicians formulated these drugs according to indications that were classified as reasonable.
To our knowledge this is the first study in Colombia and the region that analyzes the inappropriate prescription of antiulcer drugs, in this case hospital prescriptions, and is one of the few in the world to carry out an economic analysis of such behavior. The number of patients included (n = 778) greatly exceeds that of other described studies (24, (26) (27) (28) . New research should be carried out on antiulcer prescriptions after hospital discharge, and comparisons of adequate prescribing at university hospitals vs. non-academic hospitals, as well as evaluating the impact of implementing drug prescription guidelines (27, 28, 34, 35) . It is necessary to carry out more studies on the economic consequences of drug inadequate use, especially in the antiulcer group.
At our hospital (Hospital Universitario San Jorge) there was a lower rate of unjustified antiulcer drug prescriptions when comparing to other institutions; nonetheless, it is still high and alarming for the important costs incurred by the hospital to pay for medicines patients do not need; also, even though an initial prescription was unjustified, very few of the antiulcer drug therapies were suspended during the whole stay in the hospital.
The new information learned must be used to modify hospital prescription practices and implement changes/ strategies that improve patient security and allow better and more economical use of resources. It is necessary that all related works determine economic indicators such as DHD and cost per 100 beds per day that will allow other researchers to make comparisons among different populations and hospitals. Some authors have proposed intervention measures for this problem, with the best results shown by adhesion to clinical practice guidelines and evidence-based protocols (7, 37, 38) .
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